Cited 3 times in
Clinical outcomes in patients with diffuse large B cell lymphoma with a partial response to first-line R-CHOP chemotherapy: prognostic value of secondary International Prognostic Index scores and Deauville scores
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김수정 | - |
dc.contributor.author | 김유리 | - |
dc.contributor.author | 김진석 | - |
dc.date.accessioned | 2018-07-20T08:18:19Z | - |
dc.date.available | 2018-07-20T08:18:19Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 0939-5555 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/161073 | - |
dc.description.abstract | After introducing a rituximab-containing chemoimmunotherapy (R-CHOP) for diffuse large B cell lymphoma (DLBCL), a partial response (PR) which is regarded as treatment failure is still observed. To investigate the prognostic factors for the DLBCL patients with a PR to R-CHOP, we retrospectively evaluated 758 newly diagnosed DLBCL patients. After R-CHOP, 88 (11.6%) achieved a PR. Three-year progression-free and overall survival rates measured from the date of PR achievement (PFS2 and OS2) were 57.4 and 67.8%, respectively. The secondary International Prognostic Index (IPI2) scores after R-CHOP were low (0-1) in 68.2% and high (2-3) in 31.8% of the patients. The Deauville scores from 18-fluorodeoxyglucose positron emission tomography after R-CHOP showed low (2-3) in 58.0% and high (4) in 42.0% of the patients. High IPI2 and high Deauville scores were associated with worse PFS2 (P < 0.001 and P = 0.009) and OS2 (P = 0.013 and P = 0.067). The high-risk group defined by the IPI2 and Deauville scores, whose scores were both high, showed significantly lower 3-year PFS2 (P < 0.001) and OS2 (P = 0.006) rates compared with those of the other groups. In multivariate analyses, the IPI score of ≥ 3 at diagnosis and bone marrow involvement at diagnosis were independent prognostic factors. In addition, high IPI2-Deauville score after R-CHOP was significantly associated with poor PFS2 (P = 0.009) and demonstrated a trend toward inferior OS2. In conclusion, DLBCL patients who partially responded to R-CHOP are still a heterogeneous group, for which IPI2 and Deauville scores should be evaluated for prediction of prognosis. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Springer International | - |
dc.relation.isPartOf | ANNALS OF HEMATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antibodies, Monoclonal, Murine-Derived/administration & dosage | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/administration & dosage* | - |
dc.subject.MESH | Cyclophosphamide/administration & dosage | - |
dc.subject.MESH | Doxorubicin/administration & dosage | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Internationality | - |
dc.subject.MESH | Lymphoma, Large B-Cell, Diffuse/diagnosis* | - |
dc.subject.MESH | Lymphoma, Large B-Cell, Diffuse/drug therapy* | - |
dc.subject.MESH | Lymphoma, Large B-Cell, Diffuse/mortality | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Prednisone/administration & dosage | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Severity of Illness Index* | - |
dc.subject.MESH | Survival Rate/trends | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Vincristine/administration & dosage | - |
dc.subject.MESH | Young Adult | - |
dc.title | Clinical outcomes in patients with diffuse large B cell lymphoma with a partial response to first-line R-CHOP chemotherapy: prognostic value of secondary International Prognostic Index scores and Deauville scores | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Hyewon Lee | - |
dc.contributor.googleauthor | Yu Ri Kim | - |
dc.contributor.googleauthor | Soo-Jeong Kim | - |
dc.contributor.googleauthor | Yong Park | - |
dc.contributor.googleauthor | Hyeon-Seok Eom | - |
dc.contributor.googleauthor | Sung Yong Oh | - |
dc.contributor.googleauthor | Hyo Jung Kim | - |
dc.contributor.googleauthor | Hye Jin Kang | - |
dc.contributor.googleauthor | Won-Sik Lee | - |
dc.contributor.googleauthor | Joon Ho Moon | - |
dc.contributor.googleauthor | Young-Woong Won | - |
dc.contributor.googleauthor | Tae-Sung Kim | - |
dc.contributor.googleauthor | Jin Seok Kim | - |
dc.identifier.doi | 10.1007/s00277-017-3107-6 | - |
dc.contributor.localId | A00633 | - |
dc.contributor.localId | A00779 | - |
dc.contributor.localId | A01017 | - |
dc.relation.journalcode | J00161 | - |
dc.identifier.eissn | 1432-0584 | - |
dc.identifier.pmid | 28831584 | - |
dc.identifier.url | https://link.springer.com/article/10.1007%2Fs00277-017-3107-6 | - |
dc.subject.keyword | Deauville scores | - |
dc.subject.keyword | Diffuse large B cell lymphoma | - |
dc.subject.keyword | FDG-PET | - |
dc.subject.keyword | International Prognostic Index | - |
dc.subject.keyword | Partial response | - |
dc.contributor.alternativeName | Kim, Soo Jeong | - |
dc.contributor.alternativeName | Kim, Yu Ri | - |
dc.contributor.alternativeName | Kim, Jin Seok | - |
dc.contributor.affiliatedAuthor | Kim, Soo Jeong | - |
dc.contributor.affiliatedAuthor | Kim, Yu Ri | - |
dc.contributor.affiliatedAuthor | Kim, Jin Seok | - |
dc.citation.volume | 96 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 1873 | - |
dc.citation.endPage | 1881 | - |
dc.identifier.bibliographicCitation | ANNALS OF HEMATOLOGY, Vol.96(11) : 1873-1881, 2017 | - |
dc.identifier.rimsid | 60963 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.